Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.
You may also be interested in...
BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key
Will activist investors succeed in unlocking Bristol-Myers Squibb's shareholder value - or instead orchestrate a takeover worth more than $100bn?
Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.
Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.